Abstract: An electrode unit for an electrochemical device, comprising (i) a solid electrolyte which divides a space for molten cathode material, selected from the group consisting of elemental sulfur and polysulfide of the alkali metal anode material, and a space for molten alkali metal anode material, and (ii) a porous solid state electrode directly adjacent to the solid electrolyte within the space for the cathode material, with a non-electron-conducting intermediate layer S present between the solid state electrode and the solid electrolyte, wherein this intermediate layer S has a thickness in the range from 0.

Abstract: Use of a composition comprising A) from 55 to 90% by weight of aluminum oxide, B) from 5 to 35% by weight of a sodium compound which at a pH of 7 at 20° C. has a solubility in water of ?300 g/l and can be converted by thermal means virtually exclusively into sodium oxide as only solid, C) from 0 to 15% by weight of a magnesium compound and/or a lithium compound selected from the group consisting of: magnesium oxide, magnesium carbonate, magnesium nitrate, lithium oxide, lithium carbonate, lithium nitrate and D) from 0 to 30% by weight of zirconium dioxide for producing a shaped ceramic body by extrusion.

Abstract: An electrode unit for an electrochemical device, comprising (i) a solid electrolyte which divides a space for molten cathode material, selected from the group consisting of elemental sulfur and polysulfide of the alkali metal anode material, and a space for molten alkali metal anode material, and (ii) a porous solid state electrode directly adjacent to the solid electrolyte within the space for the cathode material, with a non-electron-conducting intermediate layer S present between the solid state electrode and the solid electrolyte, wherein this intermediate layer S has a thickness in the range from 0.

Abstract: Use of a composition comprising A) from 55 to 90% by weight of aluminum oxide, B) from 5 to 35% by weight of a sodium compound which at a pH of 7 at 20° C. has a solubility in water of ?300 g/l and can be converted by thermal means virtually exclusively into sodium oxide as only solid, C) from 0 to 15% by weight of a magnesium compound and/or a lithium compound selected from the group consisting of: magnesium oxide, magnesium carbonate, magnesium nitrate, lithium oxide, lithium carbonate, lithium nitrate and D) from 0 to 30% by weight of zirconium dioxide for producing a shaped ceramic body by extrusion.

Abstract: A method for determining the likelihood of response of an individual, suffering from a disease, towards immunoglobulin therapy has the steps of providing a sample containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individual; genotyping of at least one of the polynucleotides of an ADAMTS9-Intron; a KLHDC8A-Intron or of a flanking region of the CD14 gene, and awarding the value of 1 for the homozygous Single Nucleotide Polymorphism combinations, which suggests that the blood sample stems from a person which will not respond to immunoglobulin treatment, while awarding the value of 0 for SNP not meeting that criteria, which suggests that the blood sample stems from a person which will respond to immunoglobulin treatment.

Abstract: A method for generating a reference for determining the likelihood of response of a patient, suffering from a disease, towards immunoglobulin therapy comprising the steps of a) providing samples of a sufficient number of individuals, in particular at least 10 individuals, the samples containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individuals; b) determination of values of immune parameters which are either static, such as leukocyte subpopulations and cytokine-level in the plasma or functional, like gene expression and cytokine release after lipopolysaccharide (LPS) and/or IVIG stimulation ex vivo; c) the determined values derived from immune parameters of the samples of the individuals are ordered in quartiles and the values belonging to the 1. quartile, values distributed at the low end of the corresponding parameter, are set to “?1”, whereas values distributed in the 4.

Abstract: The present invention relates to a new process for preparing condensation resins, constructed formally from urea, formaldehyde, and CH-acidic aldehydes.

Abstract: The present invention relates to new condensation resins formed from urea, formaldehyde and CH-acidic aldehydes, to processes for preparing them, and to use thereof.

Abstract: The present invention relates to new condensation resins of urea, formaldehyde, and CH-acidic aldehydes, to methods for preparing them, and to their use.

Abstract: The present invention relates to a new process for preparing condensation resins, constructed formally from urea, formaldehyde, and CH-acidic aldehydes.

Abstract: The present invention relates to new condensation resins of urea, formaldehyde, and CH-acidic aldehydes, to methods for preparing them, and to their use.

Abstract: The present invention relates to new condensation resins formed from urea, formaldehyde and CH-acidic aldehydes, to processes for preparing them, and to use thereof.

Abstract: A method for dispersing graphite-like nanoparticles is described, wherein the graphite-like nanoparticles are dispersed in a continuous liquid phase while applying energy in the presence of the dispersing agent, using dispersing agents consisting of block copolymers, at least one block of which bears aromatic side chains that are bound via aliphatic chain links to the main chain of the block copolymer.

Abstract: A method of determining a patient's susceptibility for NK cell modulation by immunoglobulins in response to a treatment of a disease or prophylaxis of a disease with immunoglobulins wherein a modulation of natural killer cells caused by said immunoglobulins is determined.

Abstract: Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilized chlorite solutions (e.g. WFIO) and a fluoropyrimidine, 5-FU, or a 5-FU prodrug (e.g. capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilized chlorite solution in combination with a fluoropyrimidine dramatically improves the quality of life index (QOL) of a patient undergoing cancer chemotherapy. Cancers that can be treated include cancers of the pancreas, gastrointestinal, head, neck, and breast.

Abstract: Methods of determining clinical outcomes in patients suffering from a pathological condition or syndrome are provided. Levels of intracellular gene expression are measured from a clinical sample provided by the patient, and the levels are compared to reference levels. Deviations from reference levels are predictive of clinical outcomes, for example, disease progression or response to therapeutic intervention.

Abstract: Methods of determining clinical outcomes in patients suffering from a pathological condition or syndrome are provided. Levels of intracellular gene expression re measured from a clinical sample provided by the patient, and the levels are compared to reference levels. Deviations from reference levels are predictive of clinical outcomes, for example, disease progression or response to therapeutic intervention.

Abstract: Methods of determining clinical outcomes in patients suffering from a pathological condition or syndrome are provided. Levels of intracellular gene expression re measured from a clinical sample provided by the patient, and the levels are compared to reference levels. Deviations from reference levels are predictive of clinical outcomes, for example, disease progression or response to therapeutic intervention.

Abstract: The present invention is based on the surprising observation, that a high degree of expression of certain distinct Genes in peripheral blood mononuclear cells is associated with in inflammatory process with a higher probability than it is the case for other Genes. Therefore, the present invention provides a method for diagnosis of an inflammatory process comprising monitoring expression levels of 4-6 selected targets in peripheral blood mononuclear cells as compared to expression levels of said selected targets in peripheral blood mononuclear cells in healthy individuals, characterized in that over-expression or repression of the majority of said selected Genes is indicative for an inflammatory process.

Abstract: Methods of determining clinical outcomes in patients suffering from a pathological condition or syndrome are provided. Levels of intracellular gene expression re measured from a clinical sample provided by the patient, and the levels are compared to reference levels. Deviations from reference levels are predictive of clinical outcomes, for example, disease progression or response to therapeutic intervention.